Brokerages Expect Tandem Diabetes Care Inc (TNDM) to Announce -$0.24 EPS

Equities analysts expect Tandem Diabetes Care Inc (NASDAQ:TNDM) to report earnings of ($0.24) per share for the current fiscal quarter, Zacks Investment Research reports. Four analysts have provided estimates for Tandem Diabetes Care’s earnings, with the highest EPS estimate coming in at ($0.21) and the lowest estimate coming in at ($0.29). Tandem Diabetes Care reported earnings of ($1.23) per share during the same quarter last year, which would suggest a positive year-over-year growth rate of 80.5%. The firm is scheduled to issue its next earnings results on Thursday, March 7th.

According to Zacks, analysts expect that Tandem Diabetes Care will report full year earnings of ($3.18) per share for the current year, with EPS estimates ranging from ($3.83) to ($2.87). For the next fiscal year, analysts anticipate that the business will post earnings of ($0.77) per share, with EPS estimates ranging from ($1.16) to ($0.58). Zacks Investment Research’s EPS calculations are an average based on a survey of analysts that cover Tandem Diabetes Care.

Tandem Diabetes Care (NASDAQ:TNDM) last posted its quarterly earnings results on Thursday, November 1st. The medical device company reported ($0.62) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.34) by ($0.28). The firm had revenue of $46.30 million during the quarter, compared to the consensus estimate of $42.71 million. Tandem Diabetes Care had a negative net margin of 93.07% and a negative return on equity of 204.32%. Tandem Diabetes Care’s revenue was up 71.5% on a year-over-year basis. During the same quarter in the prior year, the business earned ($3.09) EPS.

Several equities analysts recently issued reports on the company. BidaskClub upgraded Tandem Diabetes Care from a “buy” rating to a “strong-buy” rating in a report on Thursday, August 23rd. Lake Street Capital raised their price target on Tandem Diabetes Care from $35.00 to $65.00 and gave the company a “buy” rating in a report on Monday, August 20th. Oppenheimer set a $38.00 price target on Tandem Diabetes Care and gave the company a “buy” rating in a report on Monday, August 6th. Dougherty & Co assumed coverage on Tandem Diabetes Care in a report on Friday, August 24th. They issued a “buy” rating and a $45.00 price target on the stock. Finally, Piper Jaffray Companies raised their price target on Tandem Diabetes Care to $32.00 and gave the company an “overweight” rating in a report on Tuesday, July 31st. Four research analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $44.27.

Tandem Diabetes Care stock opened at $39.56 on Monday. The stock has a market capitalization of $2.13 billion, a P/E ratio of -3.07 and a beta of 0.53. Tandem Diabetes Care has a 12-month low of $2.14 and a 12-month high of $52.55.

In other Tandem Diabetes Care news, CEO Kim D. Blickenstaff sold 198,000 shares of the firm’s stock in a transaction dated Wednesday, November 7th. The stock was sold at an average price of $37.01, for a total transaction of $7,327,980.00. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Richard P. Valencia bought 1,300 shares of Tandem Diabetes Care stock in a transaction on Monday, November 5th. The shares were bought at an average price of $37.75 per share, for a total transaction of $49,075.00. The disclosure for this purchase can be found here. 9.30% of the stock is currently owned by company insiders.

A number of institutional investors and hedge funds have recently modified their holdings of the business. US Bancorp DE boosted its holdings in Tandem Diabetes Care by 397.8% during the third quarter. US Bancorp DE now owns 2,489 shares of the medical device company’s stock worth $107,000 after buying an additional 1,989 shares during the last quarter. Meeder Asset Management Inc. raised its position in shares of Tandem Diabetes Care by 1,921.6% during the third quarter. Meeder Asset Management Inc. now owns 2,709 shares of the medical device company’s stock worth $116,000 after purchasing an additional 2,575 shares during the period. Wells Fargo & Company MN raised its position in shares of Tandem Diabetes Care by 11.3% during the third quarter. Wells Fargo & Company MN now owns 26,968 shares of the medical device company’s stock worth $1,155,000 after purchasing an additional 2,734 shares during the period. Rhumbline Advisers raised its position in shares of Tandem Diabetes Care by 6.8% during the third quarter. Rhumbline Advisers now owns 45,756 shares of the medical device company’s stock worth $1,960,000 after purchasing an additional 2,910 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC acquired a new stake in shares of Tandem Diabetes Care during the third quarter worth about $174,000. Hedge funds and other institutional investors own 62.80% of the company’s stock.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes various products for people with insulin-dependent diabetes in the United States. The company's flagship product is the t:slim X2 insulin delivery system that comprises t:slim X2 pump, its 300-unit disposable insulin cartridge, and an infusion set.

Featured Article: Bond

Get a free copy of the Zacks research report on Tandem Diabetes Care (TNDM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Tandem Diabetes Care (NASDAQ:TNDM)

Receive News & Ratings for Tandem Diabetes Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tandem Diabetes Care and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply